Our main question was whether we could predict the efficacy of mono- or combination therapy in certain subgroups of pancreatic cancer patients based on their kinase mutation/expression pattern and if there is a patient subgroup which yet benefits from MEK inhibitors at all. The gene discussed is MAP2K7; the disease is familial pancreatic carcinoma.